Serazapine (developmental code name CGS-15040A), or serazepine, is a serotonin 5-HT2 receptor antagonist that was investigated as a potential treatment for generalized anxiety disorder in the 1990s. In humans, serazapine was well tolerated at doses of 10 to 40 mg and was found to be superior to placebo for reducing anxiety symptoms as indicated by HAM-A scores.[1][2] However, clinical development was discontinued.[2]
Clinical data | |
---|---|
Other names | Serazepine; CGS-15040A |
Routes of administration | By mouth |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C22H23N3O2 |
Molar mass | 361.445 g·mol−1 |
3D model (JSmol) | |
| |
|
References
edit- ^ Katz RJ, Landau PS, Lott M, Bystritsky A, Diamond B, Hoehn-Saric R, et al. (1 July 1993). "Serotonergic (5-HT2) mediation of anxiety-therapeutic effects of serazepine in generalized anxiety disorder". Biological Psychiatry. 34 (1–2): 41–4. doi:10.1016/0006-3223(93)90254-b. PMID 8104044. S2CID 24119589.
- ^ a b "Serazepine". Adis Insight. Springer Nature Switzerland AG. Retrieved 8 April 2021.